	Case 3:16-cv-06506 Document 1	Filed 11/08/16 Page 1 of 25		
1 2 3 4 5 6 7 8 9 10	MARK T. JANSEN (SBN 114896) mjansen@crowell.com PILAR R. STILLWATER (SBN 260467) pstillwater@crowell.com GALEN P. SALLOMI (SBN 306743) gsallomi@crowell.com CROWELL & MORING LLP 275 Battery Street, 23rd Floor San Francisco, California 94111 Telephone: 415.986.2800 Facsimile: 415.986.2827 KATHRYN L. CLUNE (pro hac vice application atchrani@crowell.com ALI H.K. TEHRANI (pro hac vice application atehrani@crowell.com CROWELL & MORING LLP 1001 Pennsylvania Ave, NW Washington, DC 20004 Telephone: 202.624.2705			
11 12 13	Facsimile: 202.628.5116 Attorneys for Plaintiff THE REGENTS OF THE UNIVERSITY OF CALIFORNIA			
14 15 16	UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA SAN FRANCISCO DIVISION			
 17 18 19 20 21 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California Corporation, Plaintiff, v.	Case No. 3:16-cv-6506 COMPLAINT FOR PATENT INFRINGEMENT JURY TRIAL DEMANDED		
22 23 24	ATRICURE, INC., a Delaware Corporation, Defendant.			
25 26 27 28	C C	y of California ("The Regents" or "Plaintiff"), by ns and alleges against AtriCure, Inc. ("Defendant"		
LP .aw		COMPLAINT FOR PATENT INFRINGEMENT CASE NO. 3:16-cv-6506		

BACKGROUND AND NATURE OF THE ACTION

This is a civil action for patent infringement arising under the patent laws of the
 United States, 35 U.S.C. §§ 1, *et seq.*, and specifically § 271, for Defendant's infringement of
 The Regents' patents covering the now-standard and universally utilized method of treating
 atrial fibrillation.

Atrial fibrillation (also referred to as "AFib" or "AF") is the most common type
of abnormal heart rhythm. AFib can be an extremely serious condition that severely limits
physical activities and significantly increases the risk of other serious heart diseases, stroke, and
death. It is estimated that five million people in the United States suffer from AFib currently,
and that this number will reach up to 12 million people by 2050. Approximately 450,000 new
cases of AFib are diagnosed in the U.S. alone each year. These figures are expected to increase
as the population ages.

Atrial fibrillation is caused by irregular electrical activity that is triggered
 typically from specific locations in the pulmonary veins, or near the entrance of the pulmonary
 veins in the left atrium of the heart. Absent appropriate treatment, the erratic electrical pulses
 travel from the pulmonary vein into the left atrium, wherein they trigger the onset of AFib,
 which causes erratic heart muscle contractions and decreases the effectiveness of the heart's
 ability to pump blood through the patient's body.

Medical researchers spent decades attempting to develop safe and effective non pharmacologic treatment methods. Dr. Michael Lesh MD, a professor of medicine and a
 cardiac electrophysiologist at the University of California, San Francisco (or "UCSF"), finally
 solved the problem by inventing the first safe and reliable minimally invasive method of
 treating AFib.

5. The treatment method invented by Dr. Lesh (the "Patented Method") involves
the formation of a circumferential conduction block at a location where a pulmonary vein
extends from the heart's left atrium. The resulting conduction block is intended to block
electrical pulses originating within or near the pulmonary vein(s) and to prevent them from
entering the left atrium and triggering atrial fibrillation. Dr. Lesh filed several related patent

Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 3 of 25

1 applications, prosecuted by and on behalf of The Regents, directed to the Patented Method, 2 including the two patents asserted in this action. All of these patents are duly assigned to The 3 Regents (collectively, "The Regents' Patents"). 4 6. AtriCure and the relevant medical community have, at all relevant times, 5 consistently referred to the Patented Method as "pulmonary vein isolation," "PVI," 6 "circumferential PVI," "circumferential conduction block," "electrical isolation of the 7 pulmonary veins," and other, similar, terms. 8 7. The Patented Method has proven highly successful in treating atrial fibrillation. 9 During the early 2000s, relevant medical professionals, such as doctors, cardiologists, cardiac 10 electrophysiologists, and cardiothoracic surgeons, universally adopted the Patented Method as 11 the accepted method of treating AFib, either alone, or in combination with other therapy. 12 8. Defendant AtriCure has, at all relevant times, been one of the major 13 manufacturers of surgical instruments and related equipment used to treat AFib. AtriCure 14 manufactures, markets, and sells a range of medical devices and related equipment (collectively, 15 "AtriCure Devices") that are used to perform the Patented Method to treat AFib. 16 9. AtriCure has, at all relevant times, had knowledge of The Regents' Patents, 17 including the two patents asserted in this action. AtriCure is also well aware of the widespread 18 use of AtriCure Devices to perform the Patented Method. Moreover, AtriCure has actively 19 induced, and continues to induce, medical professionals to use AtriCure Devices specifically to 20 practice the Patented Method. In addition, certain of the AtriCure Devices have no substantial 21 use other than to perform the Patented Method, making AtriCure liable for contributory patent 22 infringement in its marketing and sale of those devices. 23 THE PARTIES 24 10. Plaintiff The Regents is a California corporation, with a principal place of 25 business located in Oakland, California. The Regents makes up the governing board of the

CROWELL & MORING LLP Attorneys At Law

26

27

28

University of California. The Regents maintains a principal, and world-renowned, medical

research facility, the University of California, San Francisco, in the City and County of San

Francisco. All actions are done in The Regents' name, including owning property such as

Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 4 of 25

		1
1	patents and other intellectual property and entering into contracts.	
2	11. Defendant AtriCure is a Delaware corporation with corporate headquarters in	
3	West Chester, Ohio. AtriCure has at least one office and research facility located in this District.	
4	JURISDICTION AND VENUE	
5	12. This court has original and exclusive subject matter jurisdiction over this	
6	controversy pursuant to 28 U.S.C. §§ 1331 and 1338(a).	
7	13. This Court has personal jurisdiction over AtriCure because AtriCure's contacts	
8	with the State of California are significant and pervasive, and because AtriCure's contacts with	
9	California, as described in this Complaint, directly give rise to this dispute. AtriCure has at least	
10	one research facility and office in California, located in this District in San Ramon, Alameda	
11	County.	
12	14. AtriCure has conducted substantial business with individuals, hospitals, and other	
13	medical institutions and facilities throughout the State of California, including in this District, and	
14	it actively promotes and sells its medical devices and equipment, including the AtriCure Devices	
15	that are the subject of this action, throughout California. In doing so, AtriCure regularly transacts	
16	business throughout the state, and in this District, in violation of the Asserted Patents, as alleged	
17	in this Complaint. Accordingly, this Court may properly exercise personal jurisdiction over	
18	AtriCure.	
19	15. Venue is proper in this District pursuant to 28 U.S.C. §§ 1391(b) and (c) and/or	
20	1400(b) at least because AtriCure resides in this District, has a regular and established place of	
21	business in this District, and has committed acts of infringement in this District.	
22	INTRA DISTRICT ASSIGNMENT	
23	16. This is an intellectual property action to be assigned on a district-wide basis	
24	pursuant to Civil Local Rule 3-2(c).	
25	THE ASSERTED PATENTS	
26	17. On December 26, 2000, the United States Patent and Trademark Office ("USPTO")	
27	duly issued United States Patent No. 6,164,283 ("the '283 Patent"), entitled "DEVICE AND	
28	METHOD FOR FORMING A CIRCUMFERENTIAL BLOCK IN A PULMONARY VEIN."	
		l

Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 5 of 25

The Regents owns by assignment all rights, title and interest in the '283 Patent. A true and
 correct copy of the '283 Patent is attached hereto as Exhibit 1.

18. On January 7, 2003, the USPTO duly issued United States Patent No. 6,502,576
("the '576 Patent"), entitled "DEVICE AND METHOD FOR FORMING A
CIRCUMFERENTIAL BLOCK IN A PULMONARY VEIN." The Regents owns by assignment
all rights, title and interest in the '576 Patent. A true and correct copy of the '576 Patent is
attached hereto as Exhibit 2.

- 8
 - .

19.

The '283 and '576 Patents are referred to collectively as the "Asserted Patents."

9

BACKGROUND OF ATRIAL FIBRILLATION

20. Atrial fibrillation is a type of cardiac arrhythmia that causes an abnormally fast and
irregular heart rate. In patients with normal sinus rhythm, the heart is electrically excited to beat
in a synchronous, patterned fashion. In patients with a cardiac arrhythmia, however, abnormal
regions of cardiac tissue emit erratic electrical signals, disrupting the synchronous beating cycle
associated with normally conductive tissue in healthy patients.

15 21. Atrial fibrillation occurs in the upper chambers of the heart (*i.e.*, atria). In healthy
individuals, the heart's atrial and ventricular chambers (*i.e.*, the lower chambers of the heart)
17 contract in a coordinated fashion, with a normal heart rhythm between 60 and 100 beats per
18 minute.

19 22. In patients with AFib, however, the atrial chambers receive such fast and erratic
20 electrical stimulation that they can only quiver and are unable to actively pump blood from the
21 atria to the ventricles. During AFib, the two atria of the heart "beat" between 350 and 600 times
22 per minute. When this occurs, the atrioventricular node, a part of the electrical pathway between
23 the atria and the ventricles, becomes overloaded with electrical impulses trying to get to the
24 ventricles. As a result, the normal coordination between the atria and ventricles is lost, ventricles
25 develop an irregular heart rhythm, and pumping efficacy is decreased.

26 23. As a result of blood not being pumped effectively to the ventricles, blood can pool
27 in the atria, posing a serious health risk. The pooling of blood can lead to coagulation and
28 clotting. Strokes occur when a blood clot travels from the atrium, through the arterial system, to

the brain. People with AFib are five times more likely to suffer a stroke than patients without
 AFib, and more than 15% of all strokes occur in patients with AFib. Once AFib is diagnosed,
 however, treatment can reduce the risk of stroke.

4 24. In some patients, the risk of stroke may be reduced with blood thinners to prevent
5 the blood from clotting, and with anti-arrhythmic drugs to restore normal sinus rhythm. These
6 drugs often have serious side effects, such as severe bleeding, dizziness, nausea, bruising, fatigue,
7 lung disease, and ventricular arrhythmias. Further, these drugs often do not prevent further
8 episodes of AFib. If drugs are not effective or well tolerated by a patient, the treatment options
9 include a cardiac ablation procedure, the evolution of which is described more fully below.

10

11

DR. MICHAEL LESH INVENTS THE PATENTED METHOD TO TREAT ATRIAL FIBRILLATION

12 25. Early non-pharmacologic approaches to treat atrial fibrillation were surgical, and
13 involved a complex pattern of surgical incisions in both the left and right atria. The resulting
14 scarred tissue was non-conductive and hence had the potential to block the erratic electrical
15 pulses thought to cause AFib.

16 26. The early surgical efforts were reported as having some success in treating patients,
17 but these open heart surgeries were highly invasive with the heart stopped, the chest opened, and
18 the patient placed on a heart-lung machine. They also required a long recovery period, tended to
19 render the left atrium non-functional, and had a high risk of death.

20 27. In parallel with the developments of the surgical procedures described above, 21 doctors began to use catheters to ablate cardiac tissue to treat a variety of cardiac arrhythmias. 22 Catheter ablation is a much less invasive procedure than surgery and is performed by cardiac 23 electrophysiologists ("EPs") in a catheterization lab. EPs are board-certified cardiologists with 24 additional training in treating cardiac arrhythmias. In a catheter ablation procedure, the EP inserts 25 multiple specialized catheters into the patient's veins and arteries. The EP generally guides the catheters into the right atrium of the patient's heart. For procedures involving the left atrium, the 26 27 EP uses a special catheter to puncture the intra-atrial septum (*i.e.*, the wall separating the left and 28 the right atria) to access the patient's left atrium, where the desired tissue can be ablated.

Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 7 of 25

1 28. In the early 1990s, EPs began using catheter ablation in an attempt to treat AFib by 2 mimicking the surgical procedures described above. These catheter procedures typically involved 3 the creation of linear patterns of non-conductive tissue from the inside wall of the heart with a 4 goal to create lesions that were transmural (*i.e.*, through the wall from inside to out). In addition, 5 the lesions needed to be continuous (or nearly so) with no gaps. Because they took many hours to 6 complete, these procedures were very stressful for patients and resulted in safety complications 7 such as perforations of the atrium and excessive radiation exposure.

8 29. In the mid-1990s, research established that approximately 90% of the erratic
9 electrical pulses causing AFib originated somewhere in the pulmonary veins. Thereafter, treating
10 EPs attempted to cure AFib by locating and ablating the point or points (focus or foci) of
11 origination of the erratic electrical signals within the pulmonary veins.

12 30. These procedures were of limited success because the exact locations of the 13 originating foci are difficult to identify. In addition, there are often multiple originating foci 14 within each pulmonary vein, causing this methodology to be extremely time-consuming. The 15 procedure also posed safety concerns, the most serious of which was stenosis of the pulmonary 16 veins due to excessive scarring. This stenosis blocked oxygen transmission in the blood, and 17 could lead to serious lung problems and even death.

31. Dr. Lesh invented the solution to this life threatening problem. The Patented
Method is directed to forming circumferential conduction blocks at locations where the
pulmonary veins extend from a patient's left atrium. The resulting circumferential conduction
blocks prevent electrical pulses that originate from within or near the pulmonary veins from
entering the left atrium and causing AFib. This allows treatment of AFib without having to
identify, locate, or ablate the triggering foci within each pulmonary vein. At the same time, it
reduces risk of complications posed by previously-employed methods of treatment.

32. Beginning in July 1997, Dr. Lesh filed several related patent applications
disclosing and covering the Patented Method. The first of these patents was filed on July 3, 1997,
and issued on January 11, 2000, as U.S. Patent No. 6,012,457 ("the '457 Patent") entitled
"DEVICE AND METHOD FOR FORMING A CIRCUMFERENTIAL BLOCK IN A

1	PULMONARY VEIN." The Regents owns by assignment all rights, title and interest in the '457			
2	Patent. A true and correct copy of the '457 Patent is attached hereto as Exhibit 3.			
3	33. The Asserted Patents claim direct priority from the '457 Patent. More specifically,			
4	the '576 Patent is a continuation and the '283 Patent is a continuation-in-part of the '457 Patent.			
5	34. The Asserted Patents disclose and claim the Patented Method, as demonstrated in			
6	representative claims 1 and 25 of the '283 Patent, and claim 1 of the '576 Patent:			
7	Claim 1 of the '283 Patent			
8	A method for treating atrial arrhythmia in a patient, comprising:			
9	forming a circumferential conduction block in a circumferential			
10	region of tissue at a location where a pulmonary vein extends from an atrium in the patient,			
11	wherein the circumferential conduction block formed is continuous along the circumferential region of tissue, and			
12	wherein the circumferential conduction block is formed without			
13	contacting the tissue with an ablative fluid medium.			
14	Claim 25 of the '283 Patent			
15	A method for treating atrial arrhythmia in a left atrium which includes a left posterior atrial wall having a plurality			
16	of pulmonary vein ostia, comprising:			
17	forming a conduction block around a first ostium of the plurality of pulmonary vein ostia from a portion of the			
18	left posterior atrial wall which includes at least one of the other pulmonary vein ostia.			
19 20	Claim 1 of the '576 Patent			
20 21	A method for treating atrial arrhythmia in a heart of a patient,			
21 22	wherein the patient includes a plurality of pulmonary veins and			
22	each pulmonary vein extends distally along a lumenal axis from a location in an atrium of the heart, the method comprising:			
23 24	providing a medical device assembly having a distal end portion			
25	with an ablation element;			
26	positioning the ablation element at one of the locations where one of the pulmonary using extends from the atrium, wherein the one			
27	of the pulmonary veins extends from the atrium, wherein the one location is along either a funneling region of a pulmonary vein			
28	ostium of the one pulmonary vein or along a region of the one pulmonary vein comprising cardiac tissue upstream from the			
LP AW	-8- COMPLAINT FOR PATENT INFRINGEMENT CASE NO. 3:16-cv-6506			

I	Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 9 of 25		
1	pulmonary vein ostium; and		
2	using said ablation element to ablate a region of tissue that has a		
3	continuous circumferential pattern which extends about the lumenal axis of the one pulmonary vein without substantially		
4	repositioning the distal end portion.		
5	35. The Patented Method, as disclosed and claimed in the Asserted Patents, is		
6	performed using a variety of devices in either a surgical procedure or a less-invasive		
7	catheterization procedure. The Patented Method has been adopted by surgeons and surgical		
8	devices companies, such as AtriCure, as well as by EPs and electrophysiology device companies.		
9	ATRICURE'S KNOWLEDGE OF THE PATENTED METHOD		
10	AND ASSERTED PATENTS		
11	36. By the early 2000s, the Patented Method as claimed in the Asserted Patents had		
12	become recognized as the most effective means of treating atrial fibrillation and was the essential		
13	element of all non-pharmacological ablation procedures used to treat AFib. In fact, all doctors in		
14	the United States that perform surgical or catheter ablation procedures to treat AFib infringe the		
15	Asserted Patents, including at least representative claims 1 and 25 of the '283 Patent, and claim 1		
16	of the '576 Patent.		
17	37. AtriCure claims to be one of the market leaders in the surgical treatment of AFib.		
18	AtriCure has performed extensive market research on the procedures and equipment used to treat		
19	AFib. AtriCure was at all relevant times aware of the Asserted Patents and knew that the		
20	Patented Method was the universally-adopted procedure for treating AFib. Indeed, by no later		
21	than 2008, AtriCure was sponsoring medical symposia at which leading cardiothoracic surgeons		
22	("Surgeons") were taught to perform the Patented Method using AtriCure Devices.		
23	38. The Regents' Patents, and in particular the Asserted Patents, are well known in the		
24	industry, as evidenced by the fact that they are widely cited in patent applications filed by		
25	AtriCure and numerous other medical device companies. According to the USPTO's database,		
26	the '457 Patent has been cited as relevant prior art in more than 460 patents and patent		
27	applications published before 2013. The asserted '283 Patent has been cited as relevant prior art		
28	in more than 350 published U.S. patents, and the asserted '576 Patent has been cited as relevant		
.P .w	-9- COMPLAINT FOR PATENT INFRINGEMENT CASE NO. 3:16-cv-6506		

Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 10 of 25

1 prior art in more than 100 published U.S. patents.

-	prof at in more than roo published e.s. patents.		
2	39. According to the USPTO's database, AtriCure cited the '457 Patent in at least 25		
3	patent applications. As the '283 and '576 Patents are a continuation-in-part and a continuation of		
4	the '457 Patent, they contain the same disclosure as the '457 Patent cited by AtriCure in its patent		
5	applications. AtriCure also applied for and prosecuted at least three U.S. patent applications		
6	which have resulted in issued patents or published patent applications that cite the '283 Patent as		
7	prior art. Thus, AtriCure maintains a thorough knowledge of all relevant facts, technologies,		
8	inventions, published research, and other developments relating to the Patented Method.		
9	40. AtriCure also specifically discussed the Patented Method in its patent applications.		
10	For example, as set forth in the following excerpt from AtriCure's own U.S. Patent No. 8,057,471,		
11	AtriCure specifically referenced and explained the universal use of the Patented Method,		
12	explaining that the method is designed to:		
13	"provide a barrier to electrical signals that may otherwise be		
14	communicated across the ablated tissue. By way of example only, such a barrier may provide a form of treating atrial fibrillation or		
15	other conditions. For instance, where atrial fibrillation is caused by aberrant or erratic electrical signals coming from one or		
16	more pulmonary veins to one or both atria of the heart, an ablation may be provided as a barrier between such veins and atria. In other words, one or more ablations may serve to		
17	atria. In other words, one or more ablations may serve to electrically isolate one or more pulmonary veins from the atria.		
18	By preventing or substantially preventing aberrant or erratic electrical signals coming from one or more pulmonary veins from		
19	reaching the atria, a more desirable sinus rhythm may be maintained."		
20	(3:53-65 (emphasis added)).		
21	41. The Regents also provided AtriCure additional notice of the Asserted Patents. On		
22	February 1, 2016, The Regents advised AtriCure in writing that AtriCure Devices were being		
23	marketed and sold to Surgeons for use in practicing the Patented Method as claimed in the		
24	Asserted Patents. The Regents' letter (attached hereto as Exhibit 4), specifically identified the		
25	Asserted Patents and explained that they cover the Patented Method, which "involve[s] the use of		
26	various energy sources to ablate heart tissue in a circumferential pattern around the pulmonary		
27	vein, disrupting the erratic electric pulses that cause atrial fibrillation."		
28	42. Accordingly, AtriCure had actual knowledge of the Asserted Patents and that the		
I D			

Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 11 of 25

Asserted Patents cover the Patented Method at all relevant times.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

1

ATRICURE MAKES, PROMOTES AND SELLS A WIDE RANGE OF SURGICAL DEVICES THAT DOCTORS USE TO PERFORM THE PATENTED METHOD

43. During the relevant time period, AtriCure has marketed and sold multiple AtriCure Devices used by Surgeons in violation of the Asserted Patents. At all relevant times, AtriCure was aware that Surgeons used AtriCure Devices to treat AFib and to perform the Patented Method.

- 44. AtriCure operates primarily in the United States and Europe. AtriCure reports that it employs approximately 500 people worldwide. AtriCure's sole business is selling devices dedicated to treating AFib. AtriCure's reported revenue for U.S. sales of AFib treatment devices
- 45. When promoting its AtriCure Devices for treatment of AFib, AtriCure understands, and the relevant medical community understands, that it is promoting the AtriCure Devices to be used specifically to perform the Patented Method. During the relevant time period, AtriCure has marketed and sold a number of ablation catheters specifically for use by Surgeons in performing the Patented Method. These include, but are not limited to, the following:

and equipment has ranged from \$60 million in 2010 to \$102 million in 2015.

- **RF Ablation Clamps**, including but not limited to: Isolator Synergy Ablation Clamps (OLL2 / OSL2), Isolator Synergy Clamps (EML2 / EMR2), Isolator Synergy Access Clamp (EMT1).
- Other Ablation Devices and Probes, including but not limited to: Coolrail Linear Pen, Isolator Linear Pen, Isolator Transpolar Pen, AFfirm Bipolar Pacing Probe, CryoICE Cryoablation Probe (CRYO2), CryoICE Cryoablation Probe (CRYO3), CryoFORM Cryoablation Probe, CryoICE Probe for Cryoanalgesia, COBRA Fusion 50 Ablation System, COBRA Fusion 150 Ablation System, Fusion Magnetic Retriever System.
 - Minimally Invasive Devices, including but not limited to: EPi-Sense Coagulation Device, Subtle Cannula.
- 28

Other Surgical Devices, including but not limited to: Lumitip Dissection System,

	Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 12 of 25			
1	Hercules Universal Stabilizer Arms, Retractors and Blades, Retractors, Atrial Lift			
2	System, Rakes and Valve Assistants, Graspers, Scissors, Needle Holders, LiV			
3	Accessories.			
4	• Sensing Equipment, including but not limited to: ORLab System, Ablation			
5	Sensing Unit and Switch Matrix, Electrosurgical Unit.			
6	• Ablation Generators, including but not limited to: RF Generator, CryoICE BOX			
7	V6.			
8	46. Numerous AtriCure Devices, including many listed above, are specifically			
9	designed for and used by Surgeons only as a material part of performing the Patented			
10	Method. With knowledge of the Asserted Patents, AtriCure has knowingly promoted such			
11	AtriCure Devices as specifically designed for the purpose of being used by Surgeons to perform			
12	the Patented Method. These particular AtriCure Devices, which have no substantial non-			
13	infringing uses include, but are not limited to, the following:			
14	• RF Ablation Clamps , including but not limited to: Isolator Synergy Ablation			
15	Clamps (OLL2 / OSL2), Isolator Synergy Clamps (EML2 / EMR2), Isolator			
16	Synergy Access Clamp (EMT1).			
17	47. Not only is AtriCure aware that Surgeons use AtriCure Devices to perform the			
18	Patented Method-which is covered by the Asserted Patents-but it specifically intends for			
19	Surgeons to continue that use as it is critical to AtriCure's business. Indeed, AtriCure has stated			
20	that its future revenue depends on increasing acceptance by the medical community of the			
21	surgical treatment of AFib and the existence, effectiveness and, in particular, the safety of			
22	AtriCure's products. See Excerpts of AtriCure's 2013 Annual Report attached hereto as Exhibit 5,			
23	at 16.			
24	48. At all relevant times, Surgeons have used AtriCure Devices to perform the			
25	Patented Method in the United States in violation of the Asserted Patents. AtriCure has at all			
26	relevant times promoted, marketed, and advertised the AtriCure Devices to be used by Surgeons			
27	to perform the Patented Method. AtriCure was aware of and intended Surgeons to use the			
28	AtriCure Devices to specifically perform the Patented Method in violation of the Asserted Patents.			
P w	-12- COMPLAINT FOR PATENT INFRINGEMENT CASE NO. 3:16-cv-6506			

ATRICURE'S INFRINGEMENT OF THE ASSERTED PATENTS

49. AtriCure at all relevant times has induced and contributed to the infringement of
the Asserted Patents. With actual knowledge of the Asserted Patents, AtriCure actively
encouraged Surgeons to use AtriCure Devices to perform the Patented Method with specific
intent to infringe the Asserted Patents. With actual knowledge of the Asserted Patents, AtriCure
sold AtriCure Devices that have no substantial non-infringing uses, contributing to the
infringement of the Asserted Patents by Surgeons.

8 9

10

11

12

13

AtriCure's Synergy Ablation System Is Approved by The FDA for Treatment of AFib to Perform the Patented Method

50. AtriCure makes and sells AtriCure Devices specifically for surgically treating AFib by performing an FDA-approved method that includes circumferential ablation lesions that isolate the pulmonary veins, *i.e.*, the Patented Method. AtriCure's FDA-approved label specifically teaches use of AtriCure Devices according to the Patented Method.

- 51. AtriCure first sought and obtained FDA approval in 2001 to market certain 14 AtriCure Devices, specifically the Synergy Ablation System (which includes the Isolator Synergy 15 Ablation Clamps, Ablation Sensing Units and Switch Matrixes), under the FDA-approved 16 indication that the System, along with radiofrequency and cryoenergy generators, "is intended to 17 ablate soft tissue during general surgery using radiofrequency energy." As explained below, in 18 December 2011, the FDA updated the approved indication to specify the Synergy Ablation 19 System's intended and actual use as a tool to ablate cardiac tissue to treat AFib using the Patented 20 Method.
- 21
 22
 23
 24
 25
 26
 27
 28

52. Prior to 2010, AtriCure began actively marketing the Synergy Ablation System to Surgeons to perform a specific pattern of cardiac ablations that requires, as its most important step, pulmonary vein isolation (PVI). In other words, AtriCure routinely promotes and teaches Surgeons to practice the Patented Method using its Synergy Ablation System.

53. In late December 2010, after being sued by the United States Department of Justice for violations of the False Claim Act for *inter alia* promoting the non-FDA-approved (or "off-label") use of AtriCure Devices to perform the Patented Method, AtriCure submitted a

Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 14 of 25

1 Premarket Approval Application ("PMA") to the FDA seeking to expand the devices' pre-2 existing indication to include the express approval to market the Synergy Ablation System to 3 Surgeons for purposes of performing the Patented Method. As stated in the application, the goal 4 was "to have an updated label specifically for treatment of atrial fibrillation," so as to "enable 5 AtriCure to conduct training programs to ensure surgeons learn the optimal surgical technique 6 with the AtriCure Synergy Ablation System." Exhibit 6 at 9. This surgical technique includes 7 the Patented Method. A copy of relevant excerpts of the AtriCure Synergy Ablation System 8 Panel Pack Executive Summary is attached as Exhibit 6. (See especially 7-9.)

9 54. On December 14, 2011, the FDA granted AtriCure's application and approved the 10 Synergy Ablation System (PMA P100046), with an indication to "ablate cardiac tissue for the 11 treatment of persistent atrial fibrillation" in patients who are undergoing open concomitant 12 coronary artery bypass and/or valve replacement and repair. The FDA-approved label, relevant 13 excerpts of which are attached as Exhibit 7, includes specific instructions for using the Synergy 14 Ablation System to perform the Patented Method. The image reproduced below, from AtriCure's 15 FDA-approved marketing label, specifically illustrates—and promotes—using AtriCure Devices 16 to perform the Patented Method by creating the circumferential PVI lesions (highlighted in 17 yellow):

Figure 1: Maze IV Procedure Lesion Se

Table 2: Lesions for Maze IV per ABLATE Protocol

Sinclar SE Claims

Exhibit 7 at 8.

55. AtriCure advertises on its website, attached as Exhibit 8, that "[t]he Isolator Synergy Ablation Clamp is the FIRST and ONLY surgical ablation device offered with FDA approval for the treatment of Atrial Fibrillation." AtriCure specifically intends for Surgeons to

AtriCure Synergy Ablation Clamp

CROWELL & MORING LLP Attorneys At Law

18

19

20

21

22

23

24

25

26

27


Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 15 of 25

use the AtriCure Devices to perform the Patented Method to treat AFib, in violation of the
 Asserted Patents.

56. As AtriCure has told its investors "[r]egardless of the duration or type of Afib,
surgeons will create lesions in the heart tissue surrounding the pulmonary veins to create an
electrical barrier between the pulmonary veins and the atrium, or upper chambers of the
heart." Exhibit 5 at 13 (emphasis added).

AtriCure's Training of Surgeons

57. At all relevant times, AtriCure has also offered courses teaching Surgeons to use
its AtriCure Devices to perform the Patented Method. By way of example, AtriCure has offered
and continues to offer an "AtriCure Maze IV Surgical Training Course." AtriCure developed,
and promoted, the training course in partnership with recognized key opinion leaders in AFib
surgery. AtriCure's brochure advertising this program, a true and correct copy of which is
attached hereto as Exhibit 9, depicts and teaches the use of circumferential PVI ablation lesions,
according to the Patented Method of the Asserted Patents (highlighted in yellow).



Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 16 of 25

1 United States, teaching the use of and selling AtriCure Devices for treating AFib to medical 2 centers throughout the United States. AtriCure selects these sales employees based on their 3 expertise and reputation in the medical device industry and their knowledge of the requisite 4 cardiac surgery procedures and technologies for performing the Patented Method. AtriCure 5 instructs and expects its large, medically skilled sales force to meet with doctors at leading 6 institutions to provide education specifically "on the use of the Synergy System to treat certain 7 AFib patients." Exhibit 5 at 13; see also id. at 3. AtriCure reported that, as of 2013, over 1,200 8 physicians had been trained to perform the Patented Method. *Id.* at 3.

9 59. AtriCure's teaching materials, including its brochure for the "AtriCure Maze IV
10 Surgical Training Course" attached as Exhibit 9 and illustrated below, present an AtriCure sales
11 representative demonstrating how the Isolator Synergy Ablation Clamps are used to create these
12 circumferential PVI ablation lesions:




Exhibit 9 at 1.

27 //

13

14

15

16

17

18

19

20

21

22

23

24

25

28 //

1 AtriCure's Other Marketing Activities 60. AtriCure has expressly recognized that its business model depends on the 2 increasing acceptance by the medical community of AtriCure Devices as a standard surgical 3 treatment of AFib during open-heart surgical procedures, and also as a sole-therapy minimally 4 invasive procedure. 5 61. To promote this acceptance, AtriCure creates and distributes promotional materials 6 that further describe and promote the use of AtriCure Devices to perform the Patented Method. 7 As just one example, the below image from the Isolator Synergy Ablation System brochure, a true 8 and correct copy which is attached hereto as Exhibit 10, specifically demonstrates the use of 9 AtriCure's Synergy Ablation System to perform circumferential PVI, including creation of 10 circumferential ablation lesions around the PV ostia, identified as "Right antral PV isolation 11 (right PVI)," and "left antral PV isolation (left PVI)." Id. at 5. 12 13 14 15 16 17 18 19 20 21 22 23 24 PULMONARY VEINS 25 26 27 Exhibit 10 at 5. 28 CROWELL

Tricuspid Annuli

••••• Surgical Incision

7

& MORING LLP ATTORNEYS AT LAW

1	62.	To further promote the use of AtriCure Devices in performing the Patented	
2	Method, AtriCure has explained in its annual reports that it also engages in activities such as:		
3	investing in cl	linical trials to validate and promote the use of AtriCure Devices in performing the	
4	Patented Method; providing "educational grants to institutions" to teach the use of AtriCure		
5	Devices "as an AFib treatment"; sponsoring publication of peer-reviewed articles teaching the use		
6	of AtriCure Devices to perform the Patented Method; and forming advisory boards and other		
7	"consulting relationships" with cardiothoracic surgeons and other "key opinion leaders" in		
8	cardiac surgery and other specialties, to oversee AtriCure's surgical training programs and to		
9	further promote the use of AtriCure Devices to perform the Patented Method. Exhibit 5 at 14.		
10	63.	To further market and promote the sale and use of AtriCure Devices, with the	
11	specific intent	that the Devices are used by Surgeons to perform the Patented Method, AtriCure	
12	further explain	ns in its annual reports that it has done and continues to do the following:	
13	•	Funds the publication of articles on the use of AtriCure Devices to perform the	
14		Patented Method;	
15	•	Provides grants or other support to renowned Surgeons, medical teaching	
16		institutions and other "thought leaders," to teach the use of AtriCure Devices to	
17		perform the Patented Method; and	
18	•	Engages in its own extensive training of Surgeons on the use of AtriCure Devices	
19		to perform the Patented Method. Id.	
20	64.	Upon information and belief, AtriCure promoted and marketed the AtriCure	
21	Devices to perform the Patented Method throughout the 2000s. The AtriCure Devices were on		
22	the market in 2001, but were not yet approved for marketing for the treatment of AFib until 2011.		
23	As the AtriCu	re Devices were designed to perform the Patented Method, AtriCure marketed the	
24	AtriCure Devices for performing the Patented Method. Indeed, AtriCure was sued for marketing		
25	off-label use in a False Claims Act qui tam case in July 2009, which the Department of Justice		
26	eventually prosecuted. In 2010, AtriCure agreed to pay \$3.8 million to resolve the False Claims		
27	Act suit based	on its marketing of the AtriCure Devices to be used for the Patented Method.	
28	65.	AtriCure's marketing activities alleged herein were performed for the commercial	

1	purpose of selling AtriCure Devices, and were not reasonably related to the development and			
2	submission of information necessary to obtain regulatory approval from the FDA, nor were they			
3	directed to the collection of information or data necessary for filing an application with the FDA			
4	for approval to market any AtriCure Device. The AtriCure Devices promoted by AtriCure, as			
5	alleged above, were approved and on the United States market, and being used to perform the			
6	Patented Method prior to AtriCure engaging in the marketing and promotional conduct alleged			
7	herein.			
8	66. On February 1, 2016, The Regents wrote to AtriCure and advised it of The			
9	Regents' concern that AtriCure's products were being marketed and sold to doctors for use in			
10	practicing the Patented Method. AtriCure has ignored, and never even acknowledged receipt of,			
11	The Regents' letter. AtriCure has not in any way changed its marketing or promotional practices			
12	so as to stop its infringement of the Asserted Patents.			
13	COUNT I: INFRINGEMENT OF THE '283 PATENT			
14	67. Plaintiff re-alleges here all of the allegations set forth in paragraphs 1-66 above.			
15	68. At all relevant times, AtriCure had knowledge of the '283 Patent and the Patented			
16	Method.			
17	69. AtriCure induces others to infringe and/or contributorily infringes one or more			
18	claims of the '283 Patent, either literally or under the doctrine of equivalents.			
19	70. Claim 25 of the '283 Patent recites:			
20	A method for treating atrial arrhythmia in a left atrium which includes a			
21	left posterior atrial wall having a plurality of pulmonary yein ostia			
22	forming a conduction block around a first ostium of the plurality of			
23	pulmonary vein ostia from a portion of the left posterior atrial wall which includes at least one of the other pulmonary vein ostia.			
24				
25	71. The use of the AtriCure Devices by Surgeons to perform the Patented Method on			
26	patients with AFib satisfies each and every limitation of claim 25 of the '283 Patent. For example,			
27	when Surgeons use AtriCure's Synergy Ablation System including the Isolator Synergy Ablation			
28	Clamps to treat AFib, Surgeons use the clamp to form a conduction block around a pulmonary			
LP AW	-19- COMPLAINT FOR PATENT INFRINGEMENT CASE NO. 3:16-cv-6506			

Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 20 of 25

vein ostia from a portion of the left atrial wall, which includes at least one other pulmonary vein
ostia. The Surgeons' use of AtriCure's Synergy Ablation System, and related devices, to perform
the Patented Method, as described above, satisfies at least Claim 25 of the '283 Patent. At all
relevant times, AtriCure knowingly encouraged and intended Surgeons to use AtriCure Devices
to perform the Patented Method on patients who have been diagnosed with AFib as described
above, in violation of claim 25.

7 72. Upon information and belief, both by manufacturing AtriCure Devices to be used
8 in a manner that AtriCure knows infringes the '283 Patent, and by encouraging Surgeons to use
9 the AtriCure Devices in a manner that AtriCure knows infringes the '283 Patent, AtriCure is
10 inducing infringement of the '283 Patent by Surgeons in violation of 35 U.S.C. § 271(b). For
11 example, AtriCure's marketing and promotional materials tout the use of AtriCure Devices to
12 perform the Patented Method in a manner that falls within the scope of at least claim 25 of the
13 '283 Patent.

A subset of AtriCure Devices sold by AtriCure, as set forth in paragraph 46, are
material to performing the Patented Method, according to claim 25 of the '283 Patent.

74. This subset of AtriCure Devices is not a staple article or commodity of commerce,
nor suitable for substantial non-infringing uses. Moreover, by its actual knowledge of the '283
Patent, AtriCure knew that a subset of the AtriCure Devices are especially made or especially
adapted for use in a manner that infringes the '283 Patent. Accordingly, AtriCure's sale of the
subset of AtriCure Devices set forth in paragraph 46 contributes to the infringement of at least
claim 25 of the '283 Patent by Surgeons in violation of 35 U.S.C. § 271(c).

22 75. AtriCure has profited and will continue to profit from its infringement of the '283
23 Patent.

AtriCure's infringement of the '283 patent has caused and will continue to cause
The Regents substantial monetary harm, for which The Regents is entitled to receive
compensatory damages in an amount to be determined at trial, but in no event less than a
reasonable royalty.

CROWELL & MORING LLP Attorneys At Law

28

77. Further, AtriCure's infringement of the '283 Patent has been willful, deliberate,

1	and with full knowledge that the use of AtriCure Devices infringes the '283 Patent, justifying an			
2	increase in the damages to be awarded to The Regents up to three times the amount found or			
3	assessed, in accordance with 35 U.S.C. § 284.			
4	78. AtriCure's willful infringement of the '283 Patent, among other actions, renders			
5	this an exceptional case, justifying the award to The Regents of its reasonable attorney fees, in			
6	accordance with 35 U.S.C. § 285.			
7	COUNT II: INFRINGEMENT OF THE '576 PATENT			
8	79. Plaintiff re-alleges here all of the allegations set forth in paragraphs 1-66 above.			
9	80. At all relevant times, AtriCure had knowledge of the '576 Patent and the Patented			
10	Method.			
11	81. AtriCure induces others to infringe and/or contributorily infringes one or more			
12	claims of the '576 Patent, either literally or under the doctrine of equivalents.			
13	82. Claim 1 of the '576 Patent recites:			
14	A method for treating atrial arrhythmia in a heart of a patient, wherein the patient includes a plurality of pulmonary veins and each pulmonary vein extends distally along a lumenal axis from a location in an atrium of the			
15				
16	heart, the method comprising:			
17	providing a medical device assembly having a distal end portion with an ablation element:			
18	ablation element;			
19	positioning the ablation element at one of the locations where one of the pulmonary veins extends from the atrium, wherein the one location is along either a funneling region of a pulmonary vein ostium of the one pulmonary vein or along a region of the one pulmonary vein comprising cardiac tissue upstream from the pulmonary vein ostium; and			
20				
21				
22	using said ablation element to ablate a region of tissue that has a			
23	continuous circumferential pattern which extends about the lumenal axis of the one pulmonary vein without substantially repositioning the distal			
24	end portion.			
25	83. The use of AtriCure Devices by Surgeons to perform the Patented Method on			
26	patients with AFib satisfies each and every limitation of claim 1 of the '576 Patent. For example,			
27	when Surgeons use AtriCure's Synergy Ablation System to treat AFib including the Isolator			
28				

Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 22 of 25

1 Synergy Ablation Clamps and other devices, the Isolator Synergy Ablation Claims have an 2 ablation element at their distal ends. Surgeons position the ablation element of the clamps at a 3 location where one of the pulmonary veins extends from the atrium at a funneling region of a 4 pulmonary vein ostium, to ablate a region of tissue with a continuous circumferential pattern, 5 which extends about the lumenal axis of one pulmonary vein, without substantially repositioning 6 the distal end portion. The Surgeons' use of AtriCure's Synergy Ablation System, and related 7 AtriCure Devices, to perform the Patented Method, as described above, satisfies at least Claim 1 8 of the '576 Patent.

9 84. At all relevant times, AtriCure knowingly encouraged and intended Surgeons to
10 use AtriCure Devices to perform the Patented Method on patients who have been diagnosed with
11 AFib as described above, in violation of claim 1.

12 85. Upon information and belief, both by manufacturing AtriCure Devices to be used
13 in a manner that AtriCure knows infringes the '576 Patent, and by encouraging Surgeons to use
14 the AtriCure Devices in a manner that AtriCure knows infringes the '576 Patent, AtriCure is
15 inducing infringement of the '576 Patent by Surgeons in violation of 35 U.S.C. § 271(b). For
16 example, AtriCure's marketing and promotion materials tout the use of AtriCure Devices to
17 perform the Patented Method in a manner that falls within the scope of at least claim 1 of the '576
18 Patent.

19 86. A subset of AtriCure Devices sold by AtriCure, as set forth in paragraph 46, are
20 material to performing the Patented Method, according to claim 1 of the '576 Patent.

87. This subset of AtriCure Devices is not a staple article or commodity of commerce,
nor suitable for substantial non-infringing uses. Moreover, by its actual knowledge of the '576
Patent, AtriCure knew that a subset of the AtriCure Devices are especially made or especially
adapted for use in a manner than infringes the '576 Patent. Accordingly, AtriCure's sale of the
subset of AtriCure Devices set forth in paragraph 46 contributes to the infringement of at least
Claim 1 of the '576 Patent by Surgeons in violation of 35 U.S.C. § 271(c).

27 88. AtriCure has profited and will continue to profit from its infringement of the '576
28 Patent.

Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 23 of 25

1	89. AtriCure's infringement of the '576 Patent has caused and will continue to cause
2	The Regents substantial monetary harm, for which The Regents is entitled to receive
3	compensatory damages in an amount to be determined at trial, but in no event less than a
4	reasonable royalty.
5	90. Further, AtriCure's infringement of the '576 Patent has been willful, deliberate,
6	and with full knowledge that the use of AtriCure Devices infringes the '576 Patent, justifying an
7	increase in the damages to be awarded to The Regents up to three times the amount found or
8	assessed, in accordance with 35 U.S.C. § 284.
9	91. AtriCure's willful infringement of the '576 Patent, among other actions, renders
10	this an exceptional case, justifying the award to The Regents of its reasonable attorney fees, in
11	accordance with 35 U.S.C. § 285.
12	PRAYER FOR RELIEF
13	Wherefore, The Regents of the University of California respectfully requests that the
14	Court enter a judgment as follows:
15	A. That AtriCure has infringed the Asserted Patents;
16	B. Awarding The Regents damages, including enhanced damages, pursuant to 35
17	U.S.C. § 284, for AtriCure's infringement of the Asserted Patents, in an amount to be determined
18	at trial, but in no event less than a reasonable royalty;
10	
19	C. Awarding The Regents pre-judgment and post-judgment interest to compensate
19 20	C. Awarding The Regents pre-judgment and post-judgment interest to compensate The Regents for the damages it has sustained;
20	The Regents for the damages it has sustained;
20 21	The Regents for the damages it has sustained;D. Awarding The Regents all of its costs and disbursements incurred in bringing this
20 21 22	The Regents for the damages it has sustained;D. Awarding The Regents all of its costs and disbursements incurred in bringing this action;
20 21 22 23	 The Regents for the damages it has sustained; D. Awarding The Regents all of its costs and disbursements incurred in bringing this action; E. Declaring that this is an exceptional case under 35 U.S.C. § 285 and awarding The
20 21 22 23 24	 The Regents for the damages it has sustained; D. Awarding The Regents all of its costs and disbursements incurred in bringing this action; E. Declaring that this is an exceptional case under 35 U.S.C. § 285 and awarding The Regents' its reasonable attorney fees, costs, and expenses; and
20 21 22 23 24 25	 The Regents for the damages it has sustained; D. Awarding The Regents all of its costs and disbursements incurred in bringing this action; E. Declaring that this is an exceptional case under 35 U.S.C. § 285 and awarding The Regents' its reasonable attorney fees, costs, and expenses; and F. Awarding The Regents any further relief the Court deems just and proper.
 20 21 22 23 24 25 26 	 The Regents for the damages it has sustained; D. Awarding The Regents all of its costs and disbursements incurred in bringing this action; E. Declaring that this is an exceptional case under 35 U.S.C. § 285 and awarding The Regents' its reasonable attorney fees, costs, and expenses; and F. Awarding The Regents any further relief the Court deems just and proper.

	Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 24 of 25				
1	1 Respec	ctfully submitted,			
2	DATED: November 8, 2016 CROW	VELL & MORING LLP			
3	3				
4					
5	5	// <i>Mark T. Jansen</i> /// Mark T. Jansen			
6	5 H	Kathryn L. Clune Pilar R. Stillwater			
7	7	Ali H.K. Tehrani Galen P. Sallomi			
8	8	Attorneys for Plaintiff			
9		THE REGENTS OF THE JNIVERSITY OF CALIFORNIA			
10	0				
11	1				
12	2				
13	3				
14	4				
15	5				
16	5				
17	7				
18	8				
19	9				
20	0				
21	1				
22					
23	3				
24					
25					
26					
27					
28	8				
LLP Law	-2	4- COMPLAINT FOR PATENT INFRINGEMENT CASE NO. 3:16-cv-6506			

	Case 3:16-cv-06506 Document 1 Filed 11/08/16 Page 25 of 25		
1	DEMAND FOR JURY TRIAL		
2	The Regents of the University of California hereby requests a trial by a jury on all issues		
3	so triable.		
4	Respectfully submitted,		
5	DATED: November 8, 2016 CROWELL & MORING LLP		
6			
7	By: /s/ Mark T. Jansen		
8	Mark T. Jansen Kathryn L. Clune		
9 10	Pilar R. Stillwater Ali H.K. Tehrani		
10 11	Galen P. Sallomi		
11	Attorneys for Plaintiff THE REGENTS OF THE		
12	UNIVERSITY OF CALIFORNIA		
13			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
L LLP LAW	-25- COMPLAINT FOR PATENT INFRINGEMENT CASE NO. 3:16-cv-6506		